AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting
Article content
ABCL575 is a novel, half-life extended anti-OX40L monoclonal antibody that is being developed for the treatment of moderate-to-severe atopic dermatitis (AD)
In preclinical studies, ABCL575 shows potent inhibition of inflammatory pathways, favorable in vivo pharmacokinetics (PK), and potential for less frequent dosing compared to a clinical benchmark
Article content
Article content
VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) today announced preclinical data on ABCL575, which will be presented as a poster at the Society for Investigative Dermatology (SID) Annual Meeting at the Hilton Bayfront in San Diego, California.
Article content
AbCellera's presentation, which is available for viewing here, describes key properties of ABCL575, including:
Article content
Potent functional activity that is equivalent to the most advanced clinical benchmark, with inhibition of OX40L signalling and T-cell activation in vitro and significant reduction of Th2 cytokines in vivo.
Modified Fc domain that supports Fc-silencing and half-life extension, with a predicted human half-life of more than 60 days from preclinical in vivo PK data.
Positive nonclinical safety profile and favorable stability when formulated at high concentration.
Article content
'We are encouraged by our preclinical data, which show high potency and a predicted extended half-life, demonstrating potential for ABCL575 to be a best-in-class treatment for people with atopic dermatitis,' said Geoff Nichol, MB ChB, SVP, Development at AbCellera. 'We look forward to advancing this molecule into the clinic and are on track to do so this year.'
Article content
Title: Preclinical development of ABCL575, a half-life extended anti-OX40L monoclonal antibody for the treatment of autoimmune conditions
Abstract Number: 0980
Session: Translational Studies: Preclinical
Date and Time: Friday, May 9, from 4:30 p.m. to 6:00 p.m. PT
Location: Indigo Ballroom & Foyer
Article content
About ABCL575
Article content
ABCL575 is a fully human, half-life extended anti-OX40L monoclonal antibody being investigated for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications to other inflammatory and autoimmune conditions. Antibody-mediated blockade of OX40/OX40L signaling is a clinically validated mechanism to modulate inflammation. Targeting OX40L, an upstream driver of the AD inflammatory cascade, has the potential to enable broader inhibition of inflammatory pathways and more durable responses than currently approved biologics. In preclinical studies, ABCL575 shows potent inhibition of T cell-mediated inflammatory pathways, favorable tolerability, and in vivo half-life that may support less frequent dosing than current clinical-stage molecules. ABCL575 is projected to enter Phase 1 clinical trials in 2025.
Article content
About AbCellera Biologics Inc.
Article content
AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.
Article content
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
Article content
In some cases, you can identify forward-looking statements by the words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors are described under 'Risk Factors,' 'Management's Discussion and Analysis of Financial Condition and Results of Operations,' and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
10 hours ago
- CBC
'Begging in pain': Eagle Ridge Hospital patient describes harrowing experience
Les Staff had to be taken to Eagle Ridge Hospital in Port Moody, B.C., after suffering from a perforated gallbladder — and says that staff told him he had to wait 10 to 11 hours to get emergency care. Staff says that the province's minister of health, Josie Osborne, is abdicating her responsibility to fix major issues in B.C.'s ERs.
CBC
13 hours ago
- CBC
Measles may be circulating in small northeast B.C. community, says health authority
Northern Health officials have identified multiple confirmed cases of measles in the small northeast B.C. community of Wonowon since late May. It's also warning of an exposure at Fort St. John Hospital earlier this month. Wonowon is located around 90 kilometres northwest of Fort St. John, and is the site of the Halfway River First Nation reserve. The nation has a registered population of just under 300 people, and the Wonowon School says its student population comprises just under 60 kids. Members of the public have been warned to check for symptoms of the disease, which has been seeing a resurgence in Canada — particularly in Ontario, where officials have counted 2,046 confirmed and probable cases of measles as of May 31, and in Alberta. Northern Health says that it has found multiple lab-confirmed cases of the disease in Wonowon, though it did not share an exact number. As of May 31, Health Canada says B.C. has reported 12 cases of measles. "While it appears the initial case was travel-acquired, Northern Health Medical Health [officers] now believe the disease is circulating in the community," reads a statement from Northern Health. "Members of the public in Wonowon and neighbouring communities, including Fort St. John, may have been exposed in various settings in the community since late May." Northern Health adds that members of the public may have been exposed to the disease at the Fort St. John Hospital emergency area on June 2, between midnight and 4 a.m. local time. Measles is one of the most contagious diseases known to humankind. Symptoms can include a fever, coughing, a runny nose, and a blotchy red rash. While health officials say most people are immune to the disease due to prior vaccination or infection, they're advising members of the public to monitor for measles symptoms for up to three weeks, as it is spread through the air. In serious cases, measles can cause complications like inflammation of the brain, pneumonia and death. WATCH | How early can you get your child a measles shot? How early can you get your child vaccinated against the measles virus? 2 months ago Duration 3:49 Measles cases in B.C. remain low, with just five confirmed cases — all of them travel-related. But elsewhere, the numbers are exploding. Experts warn of further spread due to low vaccination rates. CBC's medical columnist, Dr. Melissa Lem, says she's been fielding questions from concerned parents. She says school-age kids are particularly vulnerable, and the virus can leave lasting damage to lungs and the immune system and even cause brain damage. They say that people at risk of getting the virus include those who have not been vaccinated against the disease or had a prior infection, with health officials across Canada saying that most of the cases they're seeing are in unvaccinated people. Two doses of the measles, mumps and rubella (MMR) vaccine or the measles, mumps, rubella and varicella (MMRV) vaccine offer almost 100 per cent effectiveness in the long term. The health authority is advising anyone in Wonowon who has been exposed to measles to call the Fort St. John Medical Clinic to book a vaccination. Officials are asking anyone who has a measles rash to self-isolate for at least four days if they're able. If anyone is experiencing severe symptoms, officials are asking them to call ahead before seeking health care so that doctors can prepare and prevent further disease spread.
CTV News
a day ago
- CTV News
Elite hockey players show position-based brain strengths, SFU research finds
A new study is shedding light on differences in brain activity between hockey players in various positions. While most athletes spend countless hours training their bodies to maximize physical performance, research conducted by experts at Simon Fraser University shows there are also benefits to mental training. 'You look at star hockey players like Connor McDavid and Nathan MacKinnon, and we may be reaching the limits of physical speed,' said lead researcher Eric Kirby, an SFU PhD graduate now with HealthTech Connex Inc. 'But the brain is highly adaptable — and we now have the tools to measure and enhance that adaptability.' Researchers used the portable NeuroCatchbrain scanner, developed by HealthTech Connex in partnership with SFU, to assess 378 elite Junior A hockey players across British Columbia. The data showed that forwards had the fastest cognitive and auditory processing speeds, while goaltenders demonstrated the strongest attentional focus. On average, the study found a 60-millisecond processing speed difference between forwards and defencemen. 'We can measure you thinking faster and we can optimize that so you're actually able to perform better from a mental processing point of view,' said Dr. Ryan D'Arcy, a neuroscientist at SFU and co-founder of NeuroCatch. 'That processing advantage not only boosts performance but also enhances safety. In contact sports, being able to read patterns and react quickly can help you avoid a hit.' D'Arcy said the scanner is lightweight, non-invasive and can be used immediately after players step off the ice, allowing for real-time evaluation of high-performance brain activity. The device measures brain activity related to sensory input, attention and cognitive function. 'NeuroCatch is like a blood pressure cuff for the brain — a portable tool to measure and track brain health,' said D'Arcy. The scan takes about six minutes and uses a soft electrode cap to record data. 'We now have an incredible list of things that allow 50 to 150 milliseconds off your ability to cognitively anticipate the play,'
